Protalex (PRTX) Stock Price, News & Analysis

Company Overview

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.

Key Stats

• Today's Range: $0.0130 to $0.0130
• 50-Day Range: $0.0130 to $0.0130
• 52-Week Range: $0.00 to $0.10
• Volume: N/A
• Average Volume: 15,694 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRTX Stock Analysis - Frequently Asked Questions

How have PRTX shares performed this year?

Protalex's stock was trading at $0.0130 at the start of the year. Since then, PRTX stock has increased by 0.0% and is now trading at $0.0130.
View the best growth stocks for 2025 here.

How were Protalex's earnings last quarter?

Protalex, Inc. (OTCMKTS:PRTX) released its earnings results on Friday, April, 13th. The company reported ($0.06) EPS for the quarter.

How do I buy shares of Protalex?

Shares of PRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Protalex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Protalex investors own include Boeing (BA), Caterpillar (CAT), Enterprise Products Partners (EPD), Eros STX Global (EROS), Global Payments (GPN), Intuitive Surgical (ISRG) and AT&T (T).

Company Calendar

• Last Earnings: 4/13/2018
• Today: 1/15/2025
• Fiscal Year End: 5/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:PRTX
• Previous Symbol: NASDAQ:PRTX
• CUSIP: N/A
• CIK: 1099215
• Web: www.protalex.com
• Phone: 215-862-9720
• Fax: 215-862-6614
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A